These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8251704)

  • 1. Comment: current treatment recommendations for leishmaniasis.
    Stein ZL
    Ann Pharmacother; 1993 Oct; 27(10):1286. PubMed ID: 8251704
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 3. Lingual leishmaniasis complicating visceral disease.
    Mazumder SA; Pandey S; Brewer SC; Baselski VS; Weina PJ; Land MA; Fleckenstein JM
    J Travel Med; 2010; 17(3):212-4. PubMed ID: 20536896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable.
    Picado A; Rijal S; Sundar S; Boelaert M
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):839-41. PubMed ID: 23030320
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.
    Pal S; Ravindran R; Ali N
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3591-3. PubMed ID: 15328135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 7. Breakthrough in the management of visceral leishmaniasis.
    Thakur BB
    J Assoc Physicians India; 2003 Jul; 51():649-51. PubMed ID: 14621030
    [No Abstract]   [Full Text] [Related]  

  • 8. Antileishmanial effect of free and encapsulated sinefungin against Leishmania donovani infections in BALB/c mice.
    Neal RA; Iwobi MV; Robert-Gero M
    C R Acad Sci III; 1989; 308(18):485-8. PubMed ID: 2508995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engima of therapeutic failure in visceral leishmaniasis.
    Arya SC
    J Assoc Physicians India; 1993 Mar; 41(3):155-8. PubMed ID: 8226600
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment options for visceral leishmaniasis.
    den Boer M; Davidson RN
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):187-97. PubMed ID: 16597201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 12. Visceral leishmaniasis in a renal transplant recipient. Short review and therapy alternative.
    Gómez Campderá F; Berenguer J; Anaya F; Rodriguez M; Valderrábano F
    Am J Nephrol; 1998; 18(2):171. PubMed ID: 9569963
    [No Abstract]   [Full Text] [Related]  

  • 13. Holiday souvenirs from the Mediterranean: three instructive cases of visceral leishmaniasis.
    Buonomano R; Brinkmann F; Leupin N; Boscacci R; Zimmermann A; Müller N; Fux CA
    Scand J Infect Dis; 2009; 41(10):777-81. PubMed ID: 19593691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal amphotericin B.
    Sundar S
    Lancet; 2001 Mar; 357(9258):801-2. PubMed ID: 11253992
    [No Abstract]   [Full Text] [Related]  

  • 15. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent.
    Olliaro PL; Shamsuzzaman TA; Marasini B; Dhariwal AC; Be-Nazir A; Mondal D; Banjara MR; Das P; Sundar S; Rijal S; Arana B; Alvar J; Argaw D; Peeling RW; Kroeger A; Matlashewski G
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005190. PubMed ID: 28125596
    [No Abstract]   [Full Text] [Related]  

  • 17. Leishmania donovanib - knocking the door.
    Kamath S; Avi H; Mehta PJ
    J Assoc Physicians India; 1995 May; 43(5):315-6. PubMed ID: 9081956
    [No Abstract]   [Full Text] [Related]  

  • 18. Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
    Croft SL; Coombs GH
    Trends Parasitol; 2003 Nov; 19(11):502-8. PubMed ID: 14580961
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of formulated amodiaquine microparticles in Leishmania donovani infected rats.
    Nettey H; Allotey-Babington GL; Somuah I; Banga NB; Afrane B; Amponsah SK; Annor H; Darko H; Hanson K; Aidoo A; Broni MN; Sasu C; Nyarko A
    J Microencapsul; 2017 Feb; 34(1):21-28. PubMed ID: 28067090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral miltefosine in the treatment of kala-azar.
    Mohan A; Seth S
    Natl Med J India; 2000; 13(4):202-3. PubMed ID: 11002688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.